ViiV Healthcare, majority owned by GSK with Shionogi as a shareholder, is committing $100 million over three years to strengthen HIV prevention, treatment, and advocacy efforts. Through its U.S. Positive Action program, the company aims to build sustainable local networks that enhance access to care.